Physician-diagnosed COPD Global Initiative for Chronic Obstructive Lung Disease stage IV in Östersund, Sweden: Patient characteristics and estimated prevalence

Chest

Volumn 130, Issue 3, 2006, Pages 666-671

  Stenfors, Nikolai ^a  

^a ÖSTERSUND HOSPITAL   (Sweden)

Author keywords

COPD; Description; Global Initiative for Chronic Obstructive Lung Disease; Prevalence; Stage IV

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; GLUCOCORTICOID; INFLUENZA VACCINE; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEMOGRAPHY; EMERGENCY TREATMENT; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; RESPIRATORY FAILURE; SMOKING; SWEDEN;

EID: 33748851330     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.3.666     Document Type: Article

References (28)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504
2. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121(suppl):121S-126S
3. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123:1684-1692
4. Bakke PS, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991; 46:863-870
5. Larsson L, Boethius G, Uddenfeldt M. Differences in utilisation of asthma drugs between two neighbouring Swedish provinces: relation to prevalence of obstructive airway disease. Thorax 1994; 49:41-49
6. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166:329-332
7. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97:115-122
8. Lindberg A, Bjerg-Backlund A, Ronmark E, et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking: report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2005
9. Lindberg A, Jonsson AC, Ronmark E, et al. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005; 72:471-479
10. 2003 update: global strategy for the diagnosis, management, and prevention of COPD. Available at: www.goldcopd.com. Accessed August 1, 2006
11. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117(suppl):339S-345S
12. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002; 51:1-16
13. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004; 9:458-465
14. Kim DS, Kim YS, Jung KS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005; 172:842-847
15. de Marco, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59:120-125
16. Hedenstrom H, Malmberg P, Agarwal K. Reference values for lung function tests in females: regression equations with smoking variables. Bull Eur Physiopathol Respir 1985; 21:551-557
17. Hedenstrom H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci 1986; 91:299-310
18. Lindstrom M, Jonsson E, Larsson K, et al. Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis 2002; 6:76-84
19. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21:68-73
20. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81
21. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
22. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919
23. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10:2794-2800
24. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121:1441-1448
25. de Groot, V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 2003; 56:221-229
26. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57:1288-1294
27. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20:799-805
28. Tsoumakidou M, Tzanakis N, Voulgaraki O, et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med 2004; 98:178-183